Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


December's 5 NMEs Filings: Ranexa, Certican, Memantine, 2 HIV Drugs

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

At least five new molecular entities reached FDA in the final month of 2002, bringing the total number of NME submissions for calendar year 2002 to 19.

You may also be interested in...

New Drug Approvals In 2003 Could Include Four HIV Agents

FDA’s new molecular entity approval totals for 2003 could feature as many as four novel HIV agents.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts